MIRA Pharmaceuticals (NASDAQ:MIRA) Posts Quarterly Earnings Results, Beats Expectations By $0.06 EPS

MIRA Pharmaceuticals (NASDAQ:MIRA) released its earnings results on Tuesday. The company reported $0.02 EPS for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.06, FiscalAI reports.

MIRA Pharmaceuticals Price Performance

Shares of MIRA opened at $1.06 on Thursday. The stock’s fifty day moving average price is $1.19 and its two-hundred day moving average price is $1.36. MIRA Pharmaceuticals has a 1 year low of $0.73 and a 1 year high of $2.45. The firm has a market cap of $44.39 million, a PE ratio of -0.69 and a beta of 1.78.

Analyst Ratings Changes

Several research firms recently weighed in on MIRA. Weiss Ratings restated a “sell (e+)” rating on shares of MIRA Pharmaceuticals in a research report on Friday, March 27th. Rodman & Renshaw started coverage on shares of MIRA Pharmaceuticals in a research report on Tuesday, January 13th. They issued a “buy” rating on the stock. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold”.

Institutional Investors Weigh In On MIRA Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the business. Creative Planning bought a new position in MIRA Pharmaceuticals during the second quarter worth about $27,000. XTX Topco Ltd purchased a new position in shares of MIRA Pharmaceuticals in the second quarter worth about $26,000. Two Sigma Investments LP raised its position in shares of MIRA Pharmaceuticals by 129.8% in the third quarter. Two Sigma Investments LP now owns 45,703 shares of the company’s stock valued at $62,000 after purchasing an additional 25,816 shares during the period. Finally, Geode Capital Management LLC raised its position in shares of MIRA Pharmaceuticals by 100.0% in the fourth quarter. Geode Capital Management LLC now owns 272,878 shares of the company’s stock valued at $412,000 after purchasing an additional 136,438 shares during the period. 35.16% of the stock is owned by hedge funds and other institutional investors.

About MIRA Pharmaceuticals

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.